Streetbeat News

Products Services

ARQQ

Arqit has entered into a reseller agreement with Phalanx, expanding its distribution channels for its encryption products. This partnership could potentially increase Arqit's market reach and sales, signaling a positive development for the company.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:09 pm

RNLX

Renalytix has announced that a real-world evidence study published after 12 months of follow-up shows that its KidneyIntelX in vitro prognostic testing is associated with clinical actions that significantly slow the progression of chronic kidney disease (CKD).

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:08 pm

ELIQ

Electriq Power Holdings, Inc. (ELIQ) plans to launch 10 new Sustainable Community Networks in Los Angeles County, California, offering zero-upfront cost solar + battery storage systems to homeowners, particularly benefiting low-to-moderate income residents. The systems aim to reduce electricity costs by up to 20%, provide price stability, and offer backup power. The PoweredUp Network program is expected to be available to roughly 400,000 residents by the end of Q1'2024.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:07 pm

TGTX

TG Therapeutics announced that its BRIUMVI product generated $40M in US net revenue for Q4 and $89M for the full year of FY23. This financial update is crucial for investors as it reflects the company's revenue-generating capability from this product.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:06 pm

AKTS

Akoustis Technologies, Inc. (NASDAQ:AKTS) has announced that its patented XBAW® filters will be used in a new quad-band enterprise Wi-Fi 7 access point platform by a Tier-1 Enterprise Wi-Fi AP Provider. The company will supply five of its filters for a 4X4 MU-MIMO Wi-Fi 7 AP router, with prototype orders already received to begin production ramp in the second half of 2024. Financial terms of the deal were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:04 pm

CLMB

JAMF

Climb Channel Solutions has announced an expanded partnership with Jamf, a leader in Apple device management. This partnership will allow Climb to offer Jamf's solutions for managing and protecting Apple devices to its network of US reseller partners, potentially increasing the reach and sales of Jamf's products.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:03 pm

AMZN

CRM

Amazon has announced the integration of Buy With Prime for Salesforce Commerce Cloud, which will start rolling out today. This integration allows Salesforce merchants to incorporate Buy with Prime into their shopping experience seamlessly. It also introduces new features such as the ability for customers to search and filter for Prime eligible items and to purchase both Prime eligible and other items in a single order.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:01 pm

CEVA

Sunplus Technology Co., Ltd. and CEVA, Inc. have expanded their collaboration to integrate Bluetooth audio into the Airlyra SoC family. This integration aims to enhance wireless speakers, soundbars, and other wireless audio devices with advanced audio features.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:01 pm

AAGR

MSS

WBUY

The article identifies three consumer staples stocks that are considered oversold based on their Relative Strength Index (RSI) values, suggesting a potential buying opportunity. Webuy Global Ltd (WBUY) announced a strategic collaboration with Ohmyhome, but its stock fell 53% over the past month. Maison Solutions Inc. (MSS) reported Q2 results and strategic growth plans, yet its stock dropped 93% over the past month. African Agriculture Holdings Inc. (AAGR) secured a supply agreement with Dr. Kahn, but its stock decreased 7% over the past five days.

Portfolio Pulse from Avi Kapoor

January 10, 2024 | 11:54 am

ALC

Alcon (NYSE:ALC) announced positive topline results from Phase 3 trials of AR-15512, a treatment for dry eye disease, showing significant improvement in tear production. The trials met the primary endpoint with statistical significance, and secondary data indicated rapid and sustained benefits. AR-15512 was well tolerated with no serious adverse events. Alcon plans to file an NDA with the FDA in mid-2024. Following the news, ALC shares rose 4.55% in premarket trading.

Portfolio Pulse from Vandana Singh

January 10, 2024 | 11:53 am